B. Metzler Seel. Sohn & Co. Ag C4 Therapeutics, Inc. Transaction History

B. Metzler Seel. Sohn & Co. Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.18 - $6.03 $18,760 - $95,870	15,899 Added 47.98%	49,037 $277,000
Q3 2023 Nov 13, 2023	SELL	$1.81 - $3.89 $59,979 - $128,906	-33,138 Reduced 50.0%	33,138 $61,000
Q2 2023 Aug 11, 2023	BUY	$2.75 - $3.77 $132,429 - $181,548	48,156 Added 265.76%	66,276 $182,000
Q1 2023 May 10, 2023	BUY	$3.1 - $9.02 $56,172 - $163,442	18,120 New	18,120 $56,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $118,040 - $187,719	14,700 New	14,700 $129,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.